Clinical trial
Macugen for Histoplasmosis
NCT00272766 · Barnes Retina Institute, Other · Terminated
Key facts
| NCT number | NCT00272766 |
|---|---|
| Title | Macugen for Histoplasmosis |
| Official title | Macugen for Histoplasmosis-An Open-Label, Single-Site, Comparative, Prospective Case Series |
| Lead sponsor | Barnes Retina Institute, Other |
| Collaborators | Pfizer Industry |
| Status | Terminated |
| Study type | Interventional |
| Conditions | Ocular Histoplasmosis, Choroidal Neovascularization |
| Intervention type | Drug |
| Interventions | pegaptanib sodium |
| Enrollment | 24 |
| Start date | Feb 1, 2006 |
| Completion | May 1, 2007 |
| First posted | Jan 9, 2006 |
| Last update posted | Oct 27, 2006 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: